ARTICLE | Clinical News
HML-115: Began Phase I testing
October 23, 2000 7:00 AM UTC
Hemosol Inc. (TSE:HML), Toronto, Ontario Product: HML-115 Business: Cancer Therapeutic category: Immune stimulation, Cytotoxic Target: Leukemia cells Description: Expanded autologous cytotoxic gamma-d...